A test report for imported medicines takes 123 working days at maximum time limits. What to file before a batch is released


An organization that imports a medicinal product into Russia (hereinafter the importer) submits two documents electronically to the Federal Service for Surveillance in Healthcare (Roszdravnadzor) before each batch or lot of the imported medicinal product, other than an immunobiological one, is released into civil circulation. These are the manufacturer’s document on the quality of the product and confirmation from a representative of that organization, authorized by the foreign manufacturer, that the product meets the registration requirements (under Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines», hereinafter 61-FZ). For an imported immunobiological medicinal product, these documents are replaced by a Roszdravnadzor permit to release each batch or lot into circulation, issued on the basis of the conclusion of a federal budgetary institution (under 61-FZ).
Medicines are imported under the procedure established by the Government of the Russian Federation, in accordance with acts of Eurasian Economic Union (EAEU) law and/or customs legislation (under 61-FZ). 61-FZ determines who may import medicines, the requirements for the medicines themselves and the documents for a shipment, and the documents required by customs.
The procedure for releasing batches into circulation was approved by Resolution of the Government of the Russian Federation No. 815 of 31 May 2025 (hereinafter Resolution No. 815). It has been in effect since 10 June 2025 and remains in force for 6 years.

Who may import medicines

Under 61-FZ, six categories of persons may import medicines (one position in the list ceased to have effect on 1 January 2024). Resolution of the Government of the Russian Federation No. 853 of 1 June 2021 (hereinafter Resolution No. 853) approved the Rules for Importing Medicines for Medical Use into the Russian Federation (hereinafter the Importation Rules). The Importation Rules name five of the six categories: medical device manufacturers are not among them (Table 1).

Table 1. Who may import medicines and on what condition

Who importsPurpose of importConditionSource
Medicine manufacturersOwn manufacture of medicines61-FZ does not name a condition of a permit for the shipment61-FZ; Importation Rules
Medicine wholesale organizations61-FZ does not name a purpose61-FZ does not name a condition of a permit for the shipment61-FZ; Importation Rules
Foreign medicine developers and foreign medicine manufacturers, or other legal entities acting on the developer’s instructionDevelopment of medicines, scientific and other research, clinical trials (CT), registration of a medicinal product, inclusion of a pharmaceutical substance in the State Register of Medicines, quality controlPermit of the authorized federal body to import a specific shipment61-FZ; Importation Rules
Scientific organizations, higher education institutions, medicine manufacturersDevelopment, research, control of the safety, quality and efficacy of medicinesPermit of the authorized federal body61-FZ; Importation Rules
Medical organizations and the organizations in the first four rows of this tableMedical care on vital indications for a specific patient; the Importation Rules add care for a limited group of patients with a rare and/or particularly severe pathologyPermit to import a specific shipment in the form of an electronic document signed with a qualified electronic signature (QES)61-FZ; Importation Rules
Medical device manufacturersManufacture of medical devices61-FZ does not name a condition61-FZ

A permit to import a specific shipment is needed for the purposes listed in 61-FZ: development of medicines, scientific and other research, CT, review of a medicine for registration, and medical care on vital indications for a specific patient. A commercial supply is not named in this list. A separate procedure for medicinal products in shortage is established by Resolution of the Government of the Russian Federation No. 593 of 5 April 2022 (hereinafter Resolution No. 593; see the section «What changes in case of a shortage and import in foreign packaging»).
If a permit is needed, the Russian Ministry of Health issues it; the Importation Rules call this document a conclusion. The applicant, that is, a legal entity from the list in the Importation Rules, completes an application in its account on the Unified Portal of State and Municipal Services and sends it to the Russian Ministry of Health. The Ministry of Health reviews the documents for no more than 5 working days (under 61-FZ and the Importation Rules). No fee is charged for issuing it (under 61-FZ and the Importation Rules). The conclusion is valid indefinitely (under the Importation Rules).
The Ministry of Health passes information on issued conclusions to customs authorities weekly. Organizations that imported a medicinal product for medical care on vital indications for a specific patient notify the Ministry of Health of this electronically within 10 working days of the medical organization receiving the products. The Importation Rules are in force until 1 September 2027. They do not apply to the import of narcotic drugs, psychotropic substances and their precursors listed in the Importation Rules themselves.

Requirements that apply to the shipment itself

The following requirements apply to an imported medicine and its documents:
the medicine is included in the State Register of Medicines or in the EAEU unified register of registered medicines (under 61-FZ);
quality is confirmed by the certificate of the medicine’s manufacturer, which attests compliance with the requirements established at registration (under 61-FZ);
import of falsified, substandard and counterfeit medicines is prohibited (under 61-FZ and the Importation Rules).

Falsified and substandard medicines are subject to seizure and then to destruction or export; counterfeit medicines are subject to seizure and destruction. Destruction or export is at the expense of the person who carried out the import (under 61-FZ).
In addition to the documents provided for by acts of the Union and by customs legislation, two more documents are submitted to customs authorities in electronic form. The first document is a certificate (conclusion) that the manufacture of a medicine for veterinary use complies with the requirements of EAEU Good Manufacturing Practice (GMP) rules. The second document is a permit to import a specific shipment in the cases for which 61-FZ requires one. Both documents are submitted to customs authorities when the medicines arrive in Russia (under 61-FZ). The first document applies to veterinary medicines, and the second to the cases where a permit for the shipment is needed, so a commercial shipment of a registered medicinal product for medical use needs no additional customs documents under 61-FZ.

What changes in case of a shortage and import in foreign packaging

61-FZ allows registered medicinal products for medical use to be imported and circulated until 31 December 2027 in packaging intended for circulation in foreign states. The date of 31 December 2027 was introduced by Federal Law No. 483-FZ of 15 December 2025, which has been in effect since 1 January 2026.
The conditions under 61-FZ are:
a shortage of the medicinal product, or a risk of one, due to restrictive economic measures against Russia;
the medicinal product meets the requirements established at registration, except the requirements for primary and secondary (consumer) packaging;
a self-adhesive label with information about the medicinal product in Russian on the secondary packaging of medicinal products in circulation.

Resolution No. 593 establishes the special provisions. It is in force through 31 December 2027.
A shortage, or a risk of one, is determined by an interdepartmental commission, whose statute and membership are approved by the Ministry of Health. The commission records its decision in a conclusion, and information on its decisions is posted on the Ministry of Health website (under Resolution No. 593).

For registered medicinal products in foreign packaging, the following procedure applies under Resolution No. 593:
import is allowed without a special permit;
transportation, sale, transfer, storage until expiry, dispensing, retail sale and use are carried out on the basis of the interdepartmental commission’s conclusion, the form of which is approved by the Ministry of Health;
each package of a batch or lot imported on the basis of the conclusion is accompanied by an instruction for medical use translated into Russian, approved by the authorized body of the country of manufacture and/or of the country of the registration holder;
the legal entity submits to the Ministry of Health, in electronic form, an application with the details of the batch or lot and the documents: information on the medicinal product registered in Russia, a power of attorney, the manufacturer’s license and a document on the manufacturer’s compliance with GMP requirements with a translation, documents on registration outside Russia, the instruction, package mock-ups and a quality control document approved in the country of manufacture or in the country of the registration holder, a summary of the pharmacovigilance system and, if available, a risk management plan;
the commission reviews the documents for 10 working days and decides to issue a conclusion or to refuse, including on the need for quality testing; grounds for refusal are incomplete or inaccurate documents and a commission conclusion that a conclusion cannot be issued;
the Ministry of Health keeps a register of issued conclusions on its website; quality testing is conducted by accredited federal budgetary institutions subordinate to the Ministry of Health and Roszdravnadzor, including remotely;
the provisions of 61-FZ on release into civil circulation (see the section «What to submit to Roszdravnadzor before releasing a batch into circulation») do not apply to such medicinal products;
when a lot manufactured outside Russia is imported (except medicinal products from EAEU member states), manufacturers apply means of identification to the packaging.

For medicinal products not registered in Russia, the Ministry of Health issues a permit for temporary circulation of a batch or lot through 31 December 2027. The permit is issued for medicinal products that are authorized for medical use in foreign states and for which the commission has found a shortage or a risk of one. Such medicinal products have analogues registered in Russia by international nonproprietary name (INN), or were registered in Russia but the registration was cancelled on the grounds named in 61-FZ. The permit is issued on the basis of a commission conclusion that a permit can be issued. Within 10 working days of receiving the documents, the Ministry of Health checks them for completeness and accuracy, sends them to the commission, arranges its meeting and, after the meeting, sends the permit to the applicant. Grounds for refusal are incomplete or inaccurate documents and a commission conclusion that a permit cannot be issued. Each package of a batch or lot is accompanied by an instruction translated into Russian. The provisions of 61-FZ on decisions following federal state control (supervision) in the sphere of the circulation of medicines, and on release into civil circulation, do not apply to such medicinal products.
61-FZ allows registered original orphan medicinal products (intended for the treatment of rare diseases) and/or advanced therapy medicinal products (ATMPs) for medical use to be imported and circulated in foreign packaging for 12 months after their registration in Russia. The shortage condition is not named here. The provisions of 61-FZ on decisions following federal state control (supervision) in the sphere of the circulation of medicines, and on the submission by manufacturers and importers of quality documents before a batch is released into circulation, do not apply to these medicinal products.
The special provisions for the import and circulation of these medicinal products were approved by Resolution of the Government of the Russian Federation No. 1231 of 24 September 2026 (hereinafter Resolution No. 1231). The resolution was published on 30 September 2026. It takes effect after 10 days from the day of its official publication and is in force for 6 years. The ConsultantPlus reference gives the effective date as 10 October 2026, with a reservation about uncertainty in counting the 10 days.
The special provisions set the following procedure:
import is governed by acts of EAEU law and/or customs legislation;
circulation of the medicinal product is based on a conclusion of the Russian Ministry of Health, and each package of a batch or lot is accompanied by an instruction for medical use translated into Russian;
the applicant, that is, a legal entity acting in its own interests or authorized to represent the interests of another legal entity, submits the application and documents through the Unified Portal or the Unified State Health Information System;
the Ministry of Health reviews the documents for 5 working days and issues a conclusion or a notice of refusal;
refusal is possible if the documents are incomplete or inaccurate, if compliance with the registration requirements (except the requirements for primary and secondary packaging) is not confirmed, if the medicinal product is not an original orphan medicinal product and/or an ATMP, and if more than 12 months have passed since registration on the day the application is filed.

The self-adhesive label on the secondary packaging must contain, among other things, the name of the medicinal product (international nonproprietary, grouping or chemical name) and the trade name, the dosage form with the dosage and the quantity in the consumer package, the name and address of the registration holder, the name and address of the manufacturer, the composition (for ATMPs, the active substance and the preservative are given; for original orphan medicinal products for oral administration, the active pharmaceutical ingredients and their quantity), the batch number, the manufacturing date and the expiry date, storage conditions and, where necessary, transportation conditions, the route of administration, dispensing conditions and warning labels, if applicable (under Resolution No. 1231).
Manufacturers apply means of identification to the secondary packaging. Data on the medicinal product and operations with it are entered in the monitoring system for the movement of medicinal products under Resolution of the Government of the Russian Federation No. 1556 of 14 December 2018 (hereinafter Resolution No. 1556; see the section «What information is entered in the monitoring system for the movement of medicinal products»).
Resolution No. 593 and Resolution No. 1231 do not provide for the submission of the conclusion to customs authorities.

How to determine the customs value

The customs value of imported goods under method 1 is determined as the transaction value: the price actually paid or payable for the goods when sold for export to the customs territory of the Union, plus the additions named in the Customs Code of the EAEU (hereinafter the EAEU Customs Code).
The method applies if all four conditions under the EAEU Customs Code are met:
there are no restrictions on the buyer’s right to use and dispose of the goods, other than a restriction on the geographic region of resale, restrictions that do not materially affect the value, and restrictions established by acts of Union bodies or the legislation of member states;
the sale and the price do not depend on conditions or obligations whose effect on the price cannot be quantified;
no part of the income or proceeds from the subsequent sale, disposal or use of the goods accrues to the seller, directly or indirectly, except in cases of additions under the EAEU Customs Code;
the buyer and the seller are not related, or are related in a way that makes the transaction value acceptable for customs purposes.

The price actually paid or payable is the total amount of all payments for the goods that the buyer has made or must make to the seller or to another person for the benefit of the seller. If part of a larger shipment of the same goods bought in one transaction is declared, the price is determined in proportion to the quantity (under the EAEU Customs Code).
The relationship between the seller and the buyer does not in itself make the transaction value unacceptable (under the EAEU Customs Code). If the customs authority detects signs that the relationship influenced the price, it informs the declarant of them and conducts customs control. The declarant may prove that there was no influence by submitting documents on the circumstances accompanying the sale, or documents confirming that the transaction value is close to a test value (under the EAEU Customs Code).

Table 2. What is added to the transaction price and what is not included in the customs value

WhatHow it is treatedSource
Remuneration to intermediaries (agents) and brokersAdded in the amount paid or payable by the buyer and not included in the price; buying commission that the buyer pays to its agent for services outside the customs territory of the Union for buying the goods is not addedEAEU Customs Code; Decision of the Board of the Eurasian Economic Commission (EEC) No. 112
Costs of containers, if for customs purposes they are considered one whole with the goods, and costs of packing, including packing materials and packing workAdded in the amount incurred or to be incurred by the buyer, if not included in the priceEAEU Customs Code
Raw materials, materials, parts, tools, dies, molds, design and development outside the customs territory of the Union that the buyer supplied free of charge or at a reduced price for the production and sale of the imported goodsThe apportioned value is added in the part not included in the priceEAEU Customs Code
Part of the income from the subsequent sale, disposal or use of the goods that accrues to the sellerAddedEAEU Customs Code
Transportation to the place of arrival in the customs territory of the Union, loading, unloading, transshipment and other related operations, insurance of these operationsAdded; another place is taken into account instead of the place of arrival if the EEC has determined itEAEU Customs Code
License and similar payments for intellectual property objects that relate to the goods and that the buyer pays as a condition of saleAdded; payments for the right of reproduction in the Union and for the right of distribution or resale (if they are not a condition of sale) are not addedEAEU Customs Code
Costs of construction, assembly, installation and servicing after import; transportation within the customs territory of the Union from the place of arrival; duties, taxes and feesNot included if separated from the price, declared by the declarant and supported by documentsEAEU Customs Code

The additions from the first six rows of Table 2 are made on the basis of reliable, quantifiable and documented information. If there is no such information, method 1 is not applied. The EAEU Customs Code allows no other additions.

The procedure for adding remuneration to intermediaries and brokers is determined by the Regulation approved by Decision of the EEC Board No. 112 of 15 July 2014 (hereinafter Decision No. 112):
a buying intermediary acts in the interests of the buyer, and a selling intermediary in the interests of the seller;
the need to add remuneration is determined by the substance of the relationship between the parties, regardless of how the person is named in the contract;
remuneration to a selling intermediary is, as a rule, included in the price of the goods; if the buyer pays it separately, it is added;
a broker’s remuneration that the buyer pays in full against the broker’s invoice, or that the seller pays in part and the buyer in part, is added in the amount in which it is not included by the seller in the price, is paid by the buyer and is not buying commission;
a person who controls the buying transaction and may make a profit or incur a loss from disposing of the goods is not considered a buying intermediary, even if the contract names the person as one;
if a buying intermediary issues the buyer an invoice with the price of the goods and its own remuneration, the price is confirmed by the sellers’ invoices, and their absence may indicate that the person bought the goods and resold them to the buyer.

Which VAT rate applies to imports

The VAT tax base on import equals the sum of the customs value, the customs duty payable and the excise duties payable; it is determined taking into account the provisions of the Tax Code of the Russian Federation (hereinafter the Tax Code) on VAT exemption and on the specifics of taxation on import of goods. The base is determined separately for each group of goods of the same name, type and brand (under the Tax Code).
The rates specified in the Tax Code apply on import. The 10 percent rate is set for medicines, including pharmaceutical substances and medicines for CT, and for medicinal products made by pharmacy organizations. The Government determines the codes of such goods. The TN VED EAEU codes (Commodity Nomenclature of Foreign Economic Activity of the EAEU) for import were approved by Resolution of the Government of the Russian Federation No. 688 of 15 September 2008 (hereinafter Resolution No. 688); section I of the list names, among others, commodity headings 3001, 3002, 3003 and 3004.
When applying the list, TN VED EAEU codes are used, taking into account the notes to the list, and the names are given for convenience; for positions marked with «*», both the code and the name are taken into account.
The codes of section I apply to three groups of goods (under the notes to the list of Resolution No. 688):
pharmaceutical substances whose data are in the State Register of Medicines or in the EAEU unified register of registered medicines;
medicinal products included in the State Register of Medicines or in the EAEU unified register that are registered in the established procedure and have a registration document;
medicines (including placebo) for CT, for the import of a specific shipment of which there is a conclusion (permit document) of the authorized federal body.

In other cases for which the Tax Code does not set another rate, taxation is at the 22 percent rate. The Russian Ministry of Finance, in its letter No. 03-07-07/57486 of 11 June 2025, considered the sale of medicines whose registration certificates have expired. The Ministry stated that the 10 percent rate does not apply to medicines that have no registration certificates, including because a certificate has expired. The Ministry referred to the note to the list of OKPD2 codes (All-Russian Classifier of Products by Economic Activity) in Resolution No. 688. The letter is informational and explanatory and does not prevent the norms from being understood differently. The notes to the TN VED EAEU list, which applies on import, also contain a condition of registration and a registration document for medicinal products.
Among the VAT exemptions on import, the Tax Code names unregistered medicines for medical care on vital indications for specific patients, provided that a permit of the federal executive body performing functions of legal regulation in the sphere of healthcare is submitted to customs authorities.

Which goods customs processes on a priority basis

The EAEU Customs Code names categories of goods for which customs operations are performed on a priority basis, including goods subject to rapid spoilage, humanitarian and technical assistance, animals, radioactive materials and express cargo. The EEC may determine other such goods and determines the list of categories of perishable goods. Medicines, vaccines and sera are not named in the EAEU Customs Code list.
The list of categories of goods subject to rapid spoilage was approved by Decision of the EEC Council No. 160 of 17 October 2022, as amended by Decision No. 130 of 24 November 2023 (hereinafter Decision No. 160).
Of the TN VED EAEU positions, those covering medicinal and biological goods that the list includes are:
2934: nucleic acids and their salts, whether or not chemically defined; other heterocyclic compounds;
3001: human organs and tissues;
3002: human blood; animal blood prepared for therapeutic, prophylactic or diagnostic use; immune sera, other blood fractions and immunological products, modified or unmodified, including those obtained by biotechnological methods; vaccines, toxins, cultures of microorganisms (except yeasts) and similar products;
3502: albumins (including concentrates of two or more whey proteins containing more than 80 wt% of whey proteins, calculated on the dry substance), albuminates and other albumin derivatives.

The list is applied by the TN VED EAEU code and the description of the goods together. Positions 3003 and 3004 are not in it.

What is needed to import narcotic drugs and psychotropic substances

Import of narcotic drugs and psychotropic substances is governed by Federal Law No. 3-FZ of 8 January 1998 «On Narcotic Drugs and Psychotropic Substances» (hereinafter 3-FZ) and requires a license for the right to import, issued by the federal executive body that carries out state regulation of foreign trade activity. The range of persons depends on the list of the substance (Table 3). Certain precursors of Table III of List IV may be imported without a license in the amounts and within the time limits set by the Government.

Table 3. Who may import narcotic drugs, psychotropic substances and precursors

What is importedWho importsSource
Narcotic drugs and psychotropic substances of Lists I and II; precursors of List I and Table I of List IVLomonosov Moscow State University for scientific and educational purposes and expert activity; state unitary enterprises3-FZ
Psychotropic substances of List III; precursors of Tables II and III of List IVLegal entities regardless of the form of ownership, except the cases of import without a license named above3-FZ

To obtain a license, a legal entity obtains a certificate for the right to import (if the substances are medicines) and a permit for the right to import, which are issued by authorized federal bodies; the certificate and the permit cannot be transferred to another legal entity. Individual entrepreneurs may not import narcotic drugs, psychotropic substances and their precursors. Customs authorities make a note on the reverse side of the license about the arrival of a specific shipment. Transit through the territory of Russia is prohibited. If the import requirements of 3-FZ are violated, the substances are subject to confiscation. These requirements do not apply in the cases that 3-FZ provides for separately.

What information is entered in the monitoring system for the movement of medicinal products

The Regulation on the monitoring system for the movement of medicinal products for medical use was approved by Resolution No. 1556 (hereinafter the monitoring system). When a medicinal product is declared and placed under the customs procedure of release for domestic consumption, the customs authority requests the packaging identification code in the monitoring system, checks it against the data of the goods declaration and transmits the release data to the monitoring system. If the declaration data change, the customs authority transmits the corrected data within 5 working days. The Federal Customs Service has access to the information of the monitoring system.

For medicinal products imported not from EAEU member states, the following procedure applies under Resolution No. 1556:
the manufacturer applies the means of identification in the form of a two-dimensional barcode to the secondary packaging, and if there is none, to the primary packaging; for a lot manufactured outside Russia, the code may be applied to a label, and the label itself applied to the packages at a customs warehouse whose address is given in the pharmaceutical activity license of the wholesale organization;
the registration holder, or the representative office of a foreign organization that holds the certificate, enters the data on the manufactured medicinal products when the packaging stage is completed (in the case of labeling at a customs warehouse, after its completion) before entering the data on further operations;
the data on import are entered by one of two procedures, which participants choose themselves, except where packages are labeled at a customs warehouse; with such labeling, before the main data are entered, the additional data listed in Resolution No. 1556 are submitted;
under the direct procedure, the registration holder or the representative office enters the data on shipment within 45 working days of the date of shipment to Russia and before the medicinal products are delivered to the place of arrival, and the importing person within 5 working days of the date of delivery and registration of the data confirms their accuracy;
under the reverse procedure, the importing person enters the import data within 5 working days of the date of delivery to the place of arrival or of completion of aggregation and before the data on the customs release decision are entered, and the registration holder or the representative office confirms their accuracy within 5 working days of the date of their registration;
after release, the importing person, or the person to whom ownership of medicinal products placed under the customs warehouse procedure has been transferred, within 5 working days of the date the medicinal products are accepted at the pharmaceutical warehouse and the release procedure is completed (or of the date of the customs release decision), enters the post-release import data, among which is the value from the accompanying documents on the basis of which the goods declaration was made, taking into account customs duties and fees.

The transfer of ownership of medicinal products under the customs warehouse procedure and the movement of medicinal products between customs control zones are also recorded in the monitoring system within 5 working days. For import from EAEU member states, the data are entered within 5 working days of the date of shipment (direct procedure) or of the date of acceptance at the pharmaceutical warehouse (reverse procedure).

What to submit to Roszdravnadzor before releasing a batch into circulation

61-FZ has no definition of release into civil circulation. The time for submitting documents is stated in 61-FZ itself: before each batch or lot is released into circulation. Imported medicinal products are released into circulation in compliance with these requirements.
Resolution No. 815 approved five sets of rules: the Rules for Submitting Documents and Information (hereinafter the Submission Rules), the Rules for Issuing a Test Report (hereinafter the Test Report Rules), the Rules for Conducting Tests (hereinafter the Testing Rules), the Rules for Issuing a Permit to Release an Immunobiological Medicinal Product into Circulation (hereinafter the Immunobiological Product Rules) and the Rules for Deciding to Terminate Civil Circulation (hereinafter the Circulation Termination Rules). The importer submits documents through its account in the automated information system of Roszdravnadzor, access to which is provided by Roszdravnadzor. The set of documents depends on the type of medicinal product (Table 4).

Table 4. What is submitted before imported medicines are released into civil circulation, and by when

What is importedWhat is submittedSource
Batch or lot of a medicinal product, other than immunobiological onesBefore release into circulation: the manufacturer’s document on the quality of the medicinal product and confirmation from a representative of the importing organization, authorized by the foreign manufacturer, that the medicinal product meets the registration requirements61-FZ; Submission Rules
Batch or lot of a pharmaceutical substanceBefore release into circulation: the manufacturer’s document on the quality of the substance61-FZ; Submission Rules
First three batches or lots of a medicinal product imported into Russia for the first time (regardless of dosage, under one registration certificate)In addition, a test report issued by accredited federal budgetary institutions subordinate to the Russian Ministry of Health and Roszdravnadzor61-FZ; Submission Rules
First batch or lot of the same medicinal productA report for the first batch or lot only, if data are submitted on the date and number of the conclusion of compliance with GMP requirements or the EAEU GMP certificate for the sites of the finished dosage form and release quality control, and in the three years before the date the report is issued there were no cases of quality non-compliance published on the Roszdravnadzor website for all sites of manufacture and release control61-FZ
Orphan medicinal products; ATMPs obtained from the biological material of a specific person and intended for use by the same personA report for the first three batches and for the first batch on GMP data is not required61-FZ
One batch or lot of an ATMP imported for the first time (except ATMPs obtained from the biological material of a specific person for the same person)A report of remote testing within the first three years after release into circulation61-FZ; Testing Rules
Medicinal product that entered circulation in the previous calendar yearEvery year no later than 1 April, a test report for one batch of the trade name, taking into account the dosage form of one dosage, from accredited testing laboratories (centers). For the orphan medicinal products and the ATMPs obtained from the biological material of a specific person for the same person, once in three years is allowed, provided the product is released into circulation. The report is not submitted if a report for the first three batches or for the first batch has already been submitted61-FZ
ATMPInstead of the annual report, may submit data on the date and number of the GMP conclusion or the EAEU GMP certificate for the sites of the finished dosage form and release quality control61-FZ
Immunobiological medicinal productRoszdravnadzor permit to release each batch or lot into circulation, issued on the basis of the conclusion of a federal budgetary institution61-FZ
Suspension or termination of import of a medicinal productNotification in electronic form not less than one year ahead to Roszdravnadzor and to the federal body that licenses the manufacture of medicines61-FZ
Medicinal product in foreign packaging circulating under a conclusion of the interdepartmental commission; unregistered medicinal product circulating under a permit for temporary circulationThe provisions of 61-FZ on release into civil circulation do not applyResolution No. 593

Documents and data on quality (the manufacturer’s document, the confirmation, the report for the first three batches) and the permit for immunobiological medicinal products are not required for medicinal products for CT, for review at registration, and for unregistered medicinal products imported for help on vital indications for a specific patient or a group of patients (under 61-FZ; the separate provision on import for a group of patients ceased to have effect on 1 January 2024).
After receiving the documents and data submitted before release into circulation (the manufacturer’s document and the confirmation, test reports, the report of remote testing of an ATMP), Roszdravnadzor within 3 working days posts on its website data on the batch or lot: the date the data were entered, the number and date of the registration certificate, the trade name, the INN, the batch number, the manufacturers, the number of the normative documentation and the name of the importer or manufacturer that entered the data (under the Submission Rules). If the dossier of a medicinal product that entered circulation in the previous calendar year has been brought into compliance with EAEU requirements, the annual report is submitted once (under the Submission Rules).

How long a test report takes

The procedure for issuing the test report for the first three batches is established by the Test Report Rules and the Testing Rules. The fee for issuing a test report is RUB 1,200, and for issuing a conclusion on an immunobiological medicinal product RUB 2,000 (under Resolution No. 815). The federal institution calculates the fee for testing by the methodology of the Russian Ministry of Health and informs the applicant. The applicant sends the request to one of the federal institutions before the first three batches or lots are released into circulation. The request is accompanied by the manufacturer’s document on quality and the confirmation, a copy of the normative documentation or the normative document on quality and, for medicinal products registered under EAEU rules, mock-ups of the primary, intermediate (if any), secondary (consumer) and group (if any) packaging (under the Test Report Rules).

Table 5. Time limits for issuing a test report (working days)

StageTime limitSource
Registration of the request and check of the completeness of materials3 days from receipt of the requestTest Report Rules
Applicant’s reply to a query about an incomplete requestNo more than 30 days from receipt of the queryTest Report Rules
Review of the request, request for samples and notice of the fee3 days from receipt of the requestTest Report Rules
Submission of samples and details of the payment documentNo more than 90 days from receipt of the requestTest Report Rules
Extension of the time for submitting samples, if samples for reproducing the quality control methods have to be bought or importedNo more than 45 days; the decision is made within 3 days of receipt of the applicationTest Report Rules
TestingNo more than 30 days from receipt of samples; the time limit is extended by the time of procedures that require methods from the normative documentationTesting Rules
Issue of the report3 days from completion of testingTest Report Rules

With the maximum time limits (Table 5), the report is issued on the 123rd working day from receipt of the request: the applicant uses the whole time limit for samples (90 days), the federal institution uses the whole time limit for testing (30 days), and the report is issued on the last day of the time limit (3 days). The calculation does not include the extension of the time for samples, the time for replying to a query about an incomplete request and the extension of the time limit for procedures under the methods (under the Test Report Rules and the Testing Rules).
Testing for the first three batches and for the first batch on GMP data is conducted in person at federal institutions (under the Testing Rules). Remote testing is allowed. It is mandatory for one batch or lot of an ATMP imported for the first time, except for ATMPs obtained from the biological material of a specific person for the same person. Remote testing is conducted by a visit to the manufacturer’s site or to a laboratory authorized by it and indicated in the registration dossier, and/or online, in four cases (under the Testing Rules):
the federal institution does not have the special testing or auxiliary equipment required by the normative documentation;
the samples cannot be transported to Russia or stored;
the specifics of manufacture or quality control do not allow testing in Russia without damaging the whole batch or lot;
a test for a quality indicator in the specification can be conducted only at the manufacturer’s site or in its authorized laboratory.

In the first case, the federal institution decides on remote testing within 5 working days of receiving the request. In the other three cases, the applicant submits a separate application with a justification together with the request, and the decision is made within 5 working days. The time limit for remote testing does not exceed 30 working days from notification of the decision and is extended by the time of procedures that require methods from the normative documentation; for the online format, if the time limit is exceeded, the applicant submits an application for extension, and the time limit can be extended by no more than 30 working days.
Grounds for refusing to issue a report: the applicant did not submit the required number of samples and did not submit the details of the payment document. For remote testing, two more grounds are added: the applicant did not submit documents or submitted inaccurate documents in response to a query that the federal institution may send within 3 working days after testing (reply within 30 working days), or the manufacturer’s method and procedures do not match those described in the normative documentation.

For an immunobiological medicinal product, the federal institution issues a conclusion.
The time limits under the Immunobiological Product Rules:
the applicant submits samples within 90 working days of receiving the application;
quality testing takes no more than 30 working days, except where the testing methods require more time;
the conclusion is issued within 3 working days after testing; after remote testing, this time limit can be extended by no more than 30 working days if evidence and documents are needed in reply to a query.

Roszdravnadzor issues the permit to release into circulation within 3 working days of receiving the application. The applicant submits the application through its account in the automated information system of Roszdravnadzor or through the Unified Portal in the form of an electronic document signed with a QES (under the Immunobiological Product Rules).

When Roszdravnadzor terminates the civil circulation of a batch

If Roszdravnadzor identifies in circulation a batch or lot of a medicinal product for which the documents and data have not been submitted (the manufacturer’s document and the confirmation, test reports, the annual report or the GMP data), or a batch or lot of an immunobiological medicinal product without a permit, it decides to terminate their civil circulation until the documents are submitted or the permit is obtained (under 61-FZ and the Circulation Termination Rules). A batch is identified in federal state control (supervision) in the sphere of the circulation of medicines. Roszdravnadzor also makes a decision on information from public authorities, citizens and organizations about a batch for which documents have not been submitted (except the annual report and the GMP data for ATMPs), or about a batch of an immunobiological medicinal product without a permit: within 3 working days of receipt it checks the accuracy of the information and then makes the decision (under the Circulation Termination Rules).
For 6 months after 1 April, Roszdravnadzor analyzes the annual reports and the GMP data for ATMPs. If the documents are missing, it decides to terminate circulation until they are submitted. Roszdravnadzor issues the decision as an order within 3 working days after the day the absence of documents is identified or the information is received. The decision applies to all batches and lots for which documents have not been submitted; for the annual report and the GMP data, it covers the batches released into circulation in the previous calendar year. Roszdravnadzor notifies the manufacturer or importer and posts the information on its website within 3 working days of the order. Roszdravnadzor cancels the decision within 3 working days of the documents being entered in the automated information system or of the permit being issued.

What liability applies

For failure to submit, or late submission of, the documents and data before release into circulation and the notification of suspension or termination of import, manufacturers and importers bear liability under the legislation of the Russian Federation (under 61-FZ). 61-FZ does not specify the type of liability.
Under the Code of the Russian Federation on Administrative Offenses (hereinafter the Administrative Offenses Code), the following is punished: failure to submit, or late submission of, to the federal executive body for control and supervision in the sphere of healthcare or its territorial body, of data whose submission is mandatory under legislation in the sphere of health protection, except the cases provided for separately in the Administrative Offenses Code, or submission of knowingly inaccurate data. The fine for officials is from RUB 10,000 to RUB 15,000, and for legal entities from RUB 30,000 to RUB 70,000. This provision of the Administrative Offenses Code contains no reference to 61-FZ.
For import of medicines that do not comply with the law, the Administrative Offenses Code sets fines. Import of falsified and counterfeit medicines, as well as import of substandard medicines and unlawful import of unregistered medicines, entails for legal entities a fine from RUB 1,000,000 to RUB 5,000,000 or administrative suspension of activity for up to 90 days, and for officials a fine from RUB 100,000 to RUB 600,000. Liability arises if the actions do not contain a criminally punishable act. The note to this provision excludes administrative liability for import of substandard and unregistered medicines if the import of unregistered medicines is allowed by legislation on the circulation of medicines and legislation in the sphere of health protection, and/or such medicines are not produced in Russia, and/or they are recommended by the World Health Organization. Under 61-FZ, persons who import falsified, substandard and counterfeit medicines bear liability under the legislation of the Russian Federation.
For late entry of data in the monitoring system for the movement of medicinal products, or entry of inaccurate data, the Administrative Offenses Code sets a fine for officials from RUB 5,000 to RUB 10,000 and for legal entities from RUB 50,000 to RUB 100,000. Production or sale of medicinal products without means of identification applied, or in violation of the procedure for applying them, entails a fine for officials from RUB 5,000 to RUB 10,000 and for legal entities from RUB 50,000 to RUB 100,000 with confiscation of the objects of the offense.

What to do

Check the right to import before ordering the shipment. Check the organization against the categories in 61-FZ (Table 1) and the medicine against the register. If the shipment is intended for CT, registration or vital indications, file an application for a conclusion through the Unified Portal: the review period is no more than 5 working days (under the Importation Rules).
Prepare the documents for customs clearance. Obtain the manufacturer’s certificate, calculate the customs value with the additions under the EAEU Customs Code (Table 2) and determine the TN VED EAEU code for the VAT rate under the list of Resolution No. 688. For a medicinal product in foreign packaging, check the conditions of 61-FZ for such medicinal products, Resolution No. 593 (the conclusion of the interdepartmental commission) and Resolution No. 1231. Enter the data on import in the monitoring system for the movement of medicinal products within the time limits of Resolution No. 1556.
Submit the documents to Roszdravnadzor before releasing the batch into circulation. For each batch or lot, enter in your account the manufacturer’s document on quality and the confirmation from a representative of the importing organization, authorized by the foreign manufacturer (under the Submission Rules). For the first three batches of a medicinal product imported for the first time, file the request for a test report before the batch is released into circulation and allow for the time: if all time limits are used, the report is issued on the 123rd working day from receipt of the request (Table 5). For immunobiological medicinal products, obtain the conclusion and the permit (under the Immunobiological Product Rules).
Put 1 April and the one-year notification period in your calendar. Before 1 April, submit the annual test report or, for ATMPs, the GMP data (under 61-FZ). Submit the notification of suspension or termination of import not less than one year ahead (under 61-FZ).
Check the special regimes. Import of narcotic drugs and psychotropic substances requires a license for the right to import (under 3-FZ). For priority customs processing, check the TN VED EAEU code and the description of the goods against the list of Decision No. 160 (positions 2934, 3001, 3002, 3502).


Legal framework:

1. Federal Law No. 61-FZ of 12 April 2010 «On the Circulation of Medicines» (as amended on 4 August 2026)
2. Resolution of the Government of the Russian Federation No. 815 of 31 May 2025 «On the Procedure for Releasing Medicines for Medical Use into Civil Circulation» (together with the Rules for Submitting Documents and Information, the Rules for Issuing a Test Report, the Rules for Conducting Tests, the Rules for Issuing a Permit to Release an Immunobiological Medicinal Product into Civil Circulation, and the Rules for Deciding to Terminate Civil Circulation)
3. Resolution of the Government of the Russian Federation No. 853 of 1 June 2021 «On Approval of the Rules for Importing Medicines for Medical Use into the Russian Federation and on Recognizing Certain Acts and Certain Provisions of Certain Acts of the Government of the Russian Federation as Repealed» (as amended on 18 June 2025)
4. Resolution of the Government of the Russian Federation No. 1231 of 24 September 2026 «On Approval of the Special Provisions for the Import into the Russian Federation and Circulation in the Russian Federation of Registered Original Orphan Medicinal Products and/or Advanced Therapy Medicinal Products for Medical Use within 12 Months after the Date of Their Registration in the Russian Federation in Packaging Intended for Circulation in Foreign States»
5. Resolution of the Government of the Russian Federation No. 593 of 5 April 2022 «On Special Provisions for the Circulation of Medicines for Medical Use in Case of a Shortage or Risk of a Shortage of Medicinal Products in Connection with the Introduction of Restrictive Economic Measures against the Russian Federation» (as amended on 10 August 2026)
6. Federal Law No. 483-FZ of 15 December 2025 «On Amending Article 47 of the Federal Law ‘On the Circulation of Medicines’»
7. Resolution of the Government of the Russian Federation No. 1556 of 14 December 2018 «On Approval of the Regulation on the Monitoring System for the Movement of Medicinal Products for Medical Use» (as amended on 29 September 2025)
8. Customs Code of the Eurasian Economic Union (Annex No. 1 to the Treaty on the Customs Code of the Eurasian Economic Union)
9. Decision of the EEC Council No. 160 of 17 October 2022 «On Approval of the List of Categories of Goods Subject to Rapid Spoilage for Which Customs Operations Are Performed on a Priority Basis» (as amended on 24 November 2023)
10. Decision of the EEC Board No. 112 of 15 July 2014 «On Approval of the Regulation on Adding Remuneration to Intermediaries (Agents) and Remuneration to Brokers to the Price Actually Paid or Payable for Imported Goods»
11. Tax Code of the Russian Federation (Part Two) No. 117-FZ of 5 August 2000 (as amended on 4 August 2026)
12. Resolution of the Government of the Russian Federation No. 688 of 15 September 2008 «On Approval of the Lists of Codes of Medical Goods Subject to Value Added Tax at the Rate of 10 Percent» (as amended on 4 June 2026)
13. Federal Law No. 3-FZ of 8 January 1998 «On Narcotic Drugs and Psychotropic Substances» (as amended on 27 October 2025)
14. Code of the Russian Federation on Administrative Offenses No. 195-FZ of 30 December 2001 (as amended on 4 August 2026)
15. Letter of the Russian Ministry of Finance No. 03-07-07/57486 of 11 June 2025 on the VAT rate for the sale of medicines whose registration certificates have expired